Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefano Kim

Showing results (51-60 of 67) with videos related to

Pageof 7
Sort By:
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|January 2, 2021
Feasibility of health-related quality of life (HRQoL) assessment for cancer patients using electronic patient-reported outcome (ePRO) in daily clinical practiceGuillaume Mouillet, Antoine Falcoz, Joëlle Fritzsch, et al.
Frontiers in Oncology|August 5, 2022
A Phase II Study Evaluating the Interest to Combine UCPVax, a Telomerase CD4 T<sub>H</sub>1-Inducer Cancer Vaccine, and Atezolizumab for the Treatment of HPV Positive Cancers: VolATIL StudyMagali Rebucci-Peixoto, Angélique Vienot, Olivier Adotevi, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 30, 2022
Immunotherapy in MSI/dMMR tumors in the perioperative setting: The IMHOTEP trialClélia Coutzac, Frederic Bibeau, Meher Ben Abdelghani, et al.
BMJ Oncology|January 31, 2025
Predictive biomarkers and specific immune responses of COVID-19 mRNA vaccine in patients with cancer: prospective results from the CACOV-VAC trialLaurie Spehner, Emeline Orillard, Antoine Falcoz, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 28, 2020
PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancerCamille Evrard, Christophe Louvet, Farid El Hajbi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2018
Clinical Validity of HPV Circulating Tumor DNA in Advanced Anal Carcinoma: An Ancillary Study to the Epitopes-HPV02 TrialAlice Bernard-Tessier, Emmanuelle Jeannot, David Guenat, et al.
Experimental Hematology & Oncology|July 21, 2023
DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: a multicenter propensity score-matching studyStefano Kim, Véronique Vendrely, Angélique Saint, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 3, 2021
Pembrolizumab with Capox Bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: The FFCD 1703-POCHI trialClaire Gallois, Jean-François Emile, Stefano Kim, et al.
BMC Cancer|April 27, 2020
Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trialStefano Kim, Bruno Buecher, Thierry André, et al.
European Journal of Cancer (Oxford, England : 1990)|January 7, 2022
Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studiesMorgane Stouvenot, Aurélia Meurisse, Angélique Saint, et al.
Pageof 7

Showing results (51-60 of 67) with videos related to

Sort By:
Pageof 7
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|January 2, 2021
Feasibility of health-related quality of life (HRQoL) assessment for cancer patients using electronic patient-reported outcome (ePRO) in daily clinical practiceGuillaume Mouillet, Antoine Falcoz, Joëlle Fritzsch, et al.
Frontiers in Oncology|August 5, 2022
A Phase II Study Evaluating the Interest to Combine UCPVax, a Telomerase CD4 T<sub>H</sub>1-Inducer Cancer Vaccine, and Atezolizumab for the Treatment of HPV Positive Cancers: VolATIL StudyMagali Rebucci-Peixoto, Angélique Vienot, Olivier Adotevi, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 30, 2022
Immunotherapy in MSI/dMMR tumors in the perioperative setting: The IMHOTEP trialClélia Coutzac, Frederic Bibeau, Meher Ben Abdelghani, et al.
BMJ Oncology|January 31, 2025
Predictive biomarkers and specific immune responses of COVID-19 mRNA vaccine in patients with cancer: prospective results from the CACOV-VAC trialLaurie Spehner, Emeline Orillard, Antoine Falcoz, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 28, 2020
PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancerCamille Evrard, Christophe Louvet, Farid El Hajbi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2018
Clinical Validity of HPV Circulating Tumor DNA in Advanced Anal Carcinoma: An Ancillary Study to the Epitopes-HPV02 TrialAlice Bernard-Tessier, Emmanuelle Jeannot, David Guenat, et al.
Experimental Hematology & Oncology|July 21, 2023
DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: a multicenter propensity score-matching studyStefano Kim, Véronique Vendrely, Angélique Saint, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 3, 2021
Pembrolizumab with Capox Bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: The FFCD 1703-POCHI trialClaire Gallois, Jean-François Emile, Stefano Kim, et al.
BMC Cancer|April 27, 2020
Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trialStefano Kim, Bruno Buecher, Thierry André, et al.
European Journal of Cancer (Oxford, England : 1990)|January 7, 2022
Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studiesMorgane Stouvenot, Aurélia Meurisse, Angélique Saint, et al.
Pageof 7